Immutep (ASX:IMM) reports positive discussions with the FDA and strong survival data
Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a recent surge in trading volume. Paul Sanger: We’re talking today with Immutep (ASX:IMM). The company is a leading biotechnology company. The stock has a code of “IMM” and a market cap of $215m. We’re joined […]
Immutep (ASX:IMM) reports positive discussions with the FDA and strong survival data Read More »